{"id":"W4387135996","doi":"10.1136/ijgc-2023-esgo.22","title":"#161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Hazard ratio; Medicine; Internal medicine; Cohort; Ovarian cancer; Oncology; Progression-free survival; Proportional hazards model; Cancer; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001379859,0.0005618538,0.001341576,0.0001849577,0.0002838276,0.0008208358,0.0003845345,0.0007495882,0.006487473],"category_scores_gemma":[0.0008494232,0.0002726611,0.001874058,0.0002244574,0.0004941306,0.0006631574,0.000256579,0.002214819,0.0009115817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006010108,"about_ca_system_score_gemma":0.0009636603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006329236,"about_ca_topic_score_gemma":0.002566964,"domain_scores_codex":[0.9996457,0.0001694461,0.0000277168,0.00005049903,0.00003533998,0.00007116651],"domain_scores_gemma":[0.999521,0.0001256553,0.0001003653,0.00005092604,0.0000346284,0.0001673579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7604356,0.00849394,0.00925449,0.001412467,0.003155603,0.000263675,0.0001486332,0.003043075,0.01645862,0.0007686244,0.01060075,0.1859646],"study_design_scores_gemma":[0.5184877,0.4047926,0.04616684,0.0001909307,0.002294968,0.0005970621,0.0001124736,0.003556926,0.005945238,0.001433246,0.01633517,0.00008685882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819857,0.006263511,0.0005756503,0.001171814,0.0003539172,0.0006891307,0.00317559,0.0000886175,0.005696135],"genre_scores_gemma":[0.9772483,0.003135585,0.001427987,0.001787716,0.0002644956,0.0007897232,0.005617813,0.00006043944,0.009668126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006487473,"threshold_uncertainty_score":0.02170271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07927103726113195,"score_gpt":0.4013359282362249,"score_spread":0.322064890975093,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}